Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Stable Isotope Labeling Detects Mutated Viral Strains

By LabMedica International staff writers
Posted on 31 May 2012
A bank of molecular signatures has been constructed that will help identify the severity of virus infection from characteristic changes seen in cells.

Changes in lung cells infected with swine flu from the 2009 outbreak compared with seasonal flu have been investigated using a technique called stable isotope labeling by amino acids in cell culture (SILAC) to measure and compare thousands of different proteins in a sample.

A team of scientists at the University of Leeds (UK) working with others from the Health Protection Agency (Porton Down, UK) used the SILAC alongside mass spectrometry to identify the proteins most affected by viral infection and used these as molecular signatures to provide the “barcode” of disease.

The study revealed how several processes in the cell were affected by the virus, with most changes seen in proteins involved in cell replication. A total of 1,427 cellular proteins were identified by two or more peptides. Studies using SILAC-based quantitative proteomics vary in the cut off value used to analyze increases and decreases in the abundance of proteins. The abundance of proteins involved in mediating antiviral responses was changed in Influenza A Virus infected cells and several integrins were decreased in abundance in virus-infected cells. Taken together, both quantitative proteomics and transcriptomic approaches can be used to identify potential cellular proteins whose functions in the virus life cycle could be targeted for chemotherapeutic intervention.

Dr John Barr, one of the senior authors, said, "Swine flu affects the lungs in a similar way to seasonal flu and this was reflected in the barcodes we found for each. Using this test might have been a way to identify how lethal the 2009 swine flu pandemic was going to be, lessening worldwide panic. Our next step is to test more lethal strains of flu, such as bird flu, to see how the barcodes differ. Flu virus frequently mutates, resulting in new strains, which may be life threatening and become pandemic. If we can test new strains using our method, we can determine their potential impact on health by comparing their barcode of disease to those of viruses already studied." The study was published on May 14, 2012, in the journal Proteomics.

Related Links:
University of Leeds
Health Protection Agency


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.